Table 2

Average prices and maximum patient cost sharing before and after the reform

Average price per package (maximum patient cost-sharing before and after policy change), in €
Control groupPensioners groupMiddle-income to high-income group
Total maximum medication monthly patient share after the scheme changeMax patient share per drugNo ceiling€8 to €18 per month*No ceiling
AntiplateletNo4.3 (1.76)4.2 (0 to 0.42)4.1 (1.64 to 2.05 or 2.46)
Beta-blockers10%2.9 (0.29)3.1 (0 to 0.31)3.0 (0.30)
ACEI/ARB
(single molecule)
10%7.4 (0.74)7.5 (0 to 0.75)7.0 (0.70)
ACEI/ARB combined with another moleculeNo22.6 (9.04)21.5 (0 to 2.15)20.6 (8.24 to 10.3 or 12.36)
StatinsNo21.4 (8.56)19.0 (0 to 1.9)21.3 (8.52 to 10.65 or 12.78)
* The changes in the cost-sharing scheme defined a third group of pensioners earning >€100 000 annually, with a 60% coinsurance and a €60 ceiling. In practice, this group is barely relevant for analysis as it accounts for <0.1% of the population.
ACEI, ACE inhibitor; ARB, angiotensin II receptor blocker.